Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $672000.0.

  • Pharma's Other Non-Current Assets fell 218.34% to $672000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $672000.0, marking a year-over-year decrease of 218.34%. This contributed to the annual value of $681000.0 for FY2025, which is 101.74% down from last year.
  • Pharma's Other Non-Current Assets amounted to $672000.0 in Q3 2025, which was down 218.34% from $680000.0 recorded in Q2 2025.
  • In the past 5 years, Pharma's Other Non-Current Assets registered a high of $1.0 million during Q4 2022, and its lowest value of $596000.0 during Q2 2021.
  • In the last 5 years, Pharma's Other Non-Current Assets had a median value of $688000.0 in 2024 and averaged $792263.2.
  • Per our database at Business Quant, Pharma's Other Non-Current Assets surged by 6797.39% in 2022 and then crashed by 3235.0% in 2024.
  • Pharma's Other Non-Current Assets (Quarter) stood at $612000.0 in 2021, then skyrocketed by 67.97% to $1.0 million in 2022, then fell by 2.82% to $999000.0 in 2023, then plummeted by 31.83% to $681000.0 in 2024, then decreased by 1.32% to $672000.0 in 2025.
  • Its last three reported values are $672000.0 in Q3 2025, $680000.0 for Q2 2025, and $681000.0 during Q1 2025.